Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 245-205-8 | CAS number: 22766-83-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 06 Jun - 04 Aug 2013
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP - guideline study, tested with the source substance tetradecyl oleate (CAS 22393-85-7). According to the ECHA guidance document 'Practical guide 6: How to report read-across and categories (ECHA, 2012)', the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted in 22 Mar 1996
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD(SD)BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Italia S.p.A., Calco (Lecco), Italy
- Age at study initiation: 6 to 7 weeks
- Weight at study initiation: 191 to 204 g (males) and 172 to 179 g (females)
- Housing: From arrival to pairing: animals were housed 5 of one sex to a cage, in polysulphone solid bottomed cages measuring 59.5x38x20 cm (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Nesting material was provided inside suitable bedding bags and changed at least twice a week.
During mating: animals were housed one male to one female in clear polysulphone cages measuring approximately 43x27x18 cm with a stainless steel mesh lid and floor (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Each cage tray held absorbent material which was inspected and changed daily. After mating, the males were re-caged as they were before mating; the females were transferred to individual solid bottomed cages (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy) for the gestation period and parturition.
- Diet: laboratory rodent diet, 4 RF 21 (Mucedola S.r.l., Settimo Milanese (MI), Italy), ad libitum
- Water: drinking water, ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous carboxymethylcellulose (0.5% CMC)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The test substance was suspended in the vehicle. Formulations were prepared daily.
VEHICLE
- Concentration in vehicle: 10, 30 and 100 mg/mL for dose levels of 100, 300 and 1000 mg/kg bw/day, respectively
- Amount of vehicle: 10 mL/kg bw - Details on mating procedure:
- - M/F ratio per cage: 1 male to 1 female (monogamous).
- Length of cohabitation: The female was placed with the same male until pregnancy had occurred or 2 weeks had elapsed.
- Proof of pregnancy: Vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy.
- After 2 weeks of unsuccessful pairing replacement of first male by another male with proven fertility.
- After successful mating each pregnant female was caged singly. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability of the test substance in the vehicle were verified by gas chromatopgraphy with a flame ionisation detection (FID). Concentration verification was conducted on a weekly basis.
- Duration of treatment / exposure:
- Males: The daily administration of the test item was started two weeks before mating and lasted until test day 28 to 29, which was one day before sacrifice.
Females: The daily administration of the test item was started two weeks before mating and continued until day 3 post-partum.
Maximum: 54 days of treatment. - Frequency of treatment:
- once daily; 7 days/week
- Details on study schedule:
- not applicable for OECD 422 study
- Remarks:
- Doses / Concentrations:
100, 300 1000 mg/kg bw/day
Basis:
actual ingested - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on a 14-day range-finding study (Rossiello, 2013. RTC Study No.: 93730EXT)
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily during the study, each animal was observed and any clinical signs recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once before commencement of treatment and at least once a week thereafter, each animal was given a detailed clinical examination. Each animal was removed from the home cage and observed in an open arena. The tests included observation of changes in gait and posture, reactivity to handling, presence of clonic or tonic movements, stereotypes or bizarre behaviour and effects on the autonomic nervous system (e.g. lachrymation, piloerection, pupil size, unusual respiratory pattern).
BODY WEIGHT: Yes
- Time schedule for examinations: females: weekly from allocation to positive identification of mating and on gestation Days 0, 7, 14 and 20. Dams were also weighed on Days 1 and 4 post partum.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: The weight of food consumed by each cage of males and females was recorded weekly during the pre-mating period starting from allocation. Individual food consumption for the females was measured on gestation Days 7, 14 and 20 starting from Day 0 post coitum and on Day 4 post partum starting from Day 1 post partum.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
For further observations and examinations (water intake, haematology, clinical chemistry, neurobehaviour), see "Repeated dose toxicity: oral" (chapter 7.5.1)
OTHER:
Reproduction paramters: number of pregnant females, pre-coital time, gestation length - Oestrous cyclicity (parental animals):
- Vaginal smears were taken daily in the morning starting two weeks before pairing until a positive identification of copulation was made. The vaginal smear data were examined to determine the following: anomalies of the oestrous cycle and pre-coital interval (i.e., the number of nights paired prior to the detection of mating).
- Sperm parameters (parental animals):
- Parameters examined in P male parental generations:
testis weight, epididymis weight, and qualitative sperm staging.
In addition, the testes and epididymides were cut at 2-3 micrometer thickness and stained with Periodic Acid Schiff (PAS). The morphological evaluation of the seminiferous epithelium (staging of spermatogenic cycle) was performed. A detailed qualitative evaluation of testes was performed on 5 randomly selected control and high dose males. The evaluation took into account the tubular stages of the spermatogenic cycle, in order to identify treatment-related effects such as: missing germ cell layers or types, retained spermatids, multinucleated or apoptotic germ cells and sloughing of spermatogenic cells into the lumen. - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: litter weight, number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies
GROSS EXAMINATION OF DEAD PUPS:
Yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals [males were sacrificed on day 29 or 30]
- Maternal animals: All surviving animals [females were sacrifices on day 4 post-partum or shorty thereafter]
GROSS PATHOLOGY: Yes
-Organ weights: adrenal glands, brain (cerebrum, cerebellum, medulla/pons), epididymides, heart, kidneys, liver, ovaries with oviducts, parathyroid glands, prostate gland, seminal vesicles with coagulating glands, spleen, testes, thymus (where present), thyroid and uterus-cervix,
-Fixation: adrenal glands, bone marrow (from sternum), brain (cerebrum, cerebellum, medulla/pons), caecum, clitoral gland, colon, duodenum, epididymides, heart, ileum (including Peyer’s patches), jejunum, kidneys, liver, lungs (including mainstem bronchi), lymph nodes (mesenteric and cervical), ovaries with oviducts, parathyroid glands, pituitary gland, penis, preputial gland, prostate gland, rectum, sciatic nerve, seminal vesicles with coagulating glands, spinal column, spinal cord (cervical, thoracic, lumber), spleen, stomach, testes, thymus (where present), thyroid, trachea, urinary bladder, uterus-cervix and vagina.
HISTOPATHOLOGY: Yes, all organs that were included for fixation (5/sex of control and high dose group) - Postmortem examinations (offspring):
- SACRIFICE
- The surviving F1 offspring were sacrificed at 4 days of age.
GROSS NECROPSY
- Gross necropsy consisted of [external and internal examinations].
Dead pups and pups sacrificed at day 4 post-partum, or shortly thereafter, were carefully examined externally for gross abnormalities.
HISTOPATHOLOGY / ORGAN WEIGTHS
not performed - Statistics:
- Standard deviations were calculated as appropriate. For continuous variables the significance of the differences amongst group means was assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data. The non-parametric Kruskal-Wallis analysis of variance was used for the other parameters. Intergroup differences between the control and treated groups were assessed by the nonparametric version of the Williams test.
The criterion for statistical significance was p<0.05 - Reproductive indices:
- Male Copulatory Index (%) = No. of animals mated/No. of animals paired x 100
Male Fertility Index (%) = No. of males which induced pregnancy/ No. of males paired x 100
Female Copulatory Index (%) = No. of animals mated/No. of animals paired x 100
Female Fertility Index (%) = No. of pregnant females/No. of females paired x 100
Males and females:
Precoital interval = Mean number of days between pairing and mating - Offspring viability indices:
- Pre-implantation loss [%] = (No. of corpora lutea - No. of implantations/ No. of corpora lutea) x 100
Pre-birth loss [%] = (No. of visible implantations - total litter size at birth/ No. of visible implantations
) x 100
Pup loss at birth [%] = (Total litter size - live litter size/ Total litter size) x 100
Cumulative pup loss on Day 4 post-partum [%] = (Total litter size at birth - live litter size at Day 4/ Total litter size at birth) x 100 - Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects obseved in the study
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed in the study
- Clinical signs:
- no effects observed
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- All pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two control females had unilateral implantation but was not treatment related.
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed in the study
- Reproductive effects observed:
- not specified
Reference
No relevant clinical signs or mortality were observed in males and females throughout the study.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
No difference of toxicological significance were seen in body weight or body weight gain. No intergroup differences were seen in food consumption.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
No relevant difference in oestrous cycle was observed in treated females when compared to controls.
REPRODUCTIVE FUNCTION: SPERM MEASURES (PARENTAL ANIMALS)
Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and to the integrity of the various cell types within the different stages; regular layering in the germinal epithelium was noted.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
The number of corpora lutea, implantations, total litter size, pre-implantation loss and pre-birth loss did not differ significantly between groups. Gestation length was also comparable between groups. No differences were observed in the pre-coital interval, copulatory and fertility indices between control and treated groups.
ORGAN WEIGHTS (PARENTAL ANIMALS)
No relevant differences in terminal body weight or organ weights were seen between the controls and treated animals of both sexes
GROSS PATHOLOGY (PARENTAL ANIMALS)
No remarkable changes were noted at post mortem examination in treated animals when compared with controls.
HISTOPATHOLOGY (PARENTAL ANIMALS)
No treatment-related changes were observed. The lesions reported in control and treated animals were considered to be an expression of spontaneous and/or incidental pathology, commonly seen in this species and age under the experimental conditions.
All pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two control females had unilateral implantation. This finding was considered incidental since it was observed also in two control females.
CLINICAL SIGNS (OFFSPRING)
Clinical signs of pups such as pallor, cold to touch, small and/or bruise muzzle, were observed in control, mid- and high dose groups. No toxicological relevance was attributed to these signs since they were seen in treated as well as in control groups.
BODY WEIGHT (OFFSPRING)
Litter data including mean litter and pup weights were comparable between groups. Sex ratio of pups showed a slight increased number of males in high dose group respect to control. No toxicological relevance was attribute to the statistical significant increase observed on Day 4.
GROSS PATHOLOGY (OFFSPRING)
Decedent pups were generally autolysed. No signs were seen in pups sacrificed on Day 4 post partum.
Table 1: Fate of females: Group incidence
|
Treatment (mg/kg/bw/d) |
|||
0 |
100 |
300 |
1000 |
|
Initial group site |
10 |
10 |
10 |
10 |
Unilateral Implantation |
2 |
0 |
0 |
1 |
Total litter loss |
0 |
0 |
0 |
1 |
With live pups on day 4 post-partum |
10 |
10 |
10 |
9 |
Table 2: Implantation, pre-implantation loss data, pre-birth loss data and gestation length of females – Group mean data
Treatment (mg/kg/bw/d) |
|
Corpora Lutea |
Implantations |
Total Litter size at birth |
Pre-implantation loss % |
Pre-birth loss % |
Gestation length (days) |
|
0 |
Mean |
18.40 |
18.10 |
15.60 |
1.44 |
12.70 |
22.10 |
|
SD |
3.37 |
3.18 |
5.27 |
3.17 |
25.82 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
100 |
Mean |
16.30 |
15.80 |
14.20 |
3.26 |
10.09 |
22.10 |
|
SD |
3.23 |
3.61 |
3.49 |
8.44 |
8.48 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
300 |
Mean |
16.90 |
16.90 |
15.60 |
0.00 |
7.65 |
22.0 |
|
SD |
1.97 |
1.97 |
2.17 |
0.00 |
7.35 |
0.00 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
1000 |
Mean |
18.10 |
17.40 |
16.40 |
6.16 |
8.21 |
22.10 |
|
SD |
5.17 |
5.32 |
5.44 |
12.73 |
9.93 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
Table 3: Litter data at birth, on day 1 and on day 4 post-partum of pregnant females – Group mean data
Treatment (mg/kg/bw/d) |
|
At birth |
On day 1 post-partum |
On day 4 post-partum |
||||||
Total litter size |
Live litter size |
Pup loss (%) |
Litter weight (g) |
Mean pup weight (g) |
Live litter size |
Cumulative loss (%) |
Litter weight (g) |
Mean pup weight (g) |
||
0 |
Mean |
15.60 |
15.40 |
1.13 |
101.62 |
7.00 |
14.40 |
6.37 |
132.38 |
9.61 |
SD |
5.27 |
5.19 |
2.40 |
30.0 |
1.09 |
4.60 |
7.58 |
36.25 |
1.58 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
100 |
Mean |
14.20 |
14.20 |
0.00 |
96.87 |
7.01 |
14.10 |
0.56 |
145.70 |
10.51 |
SD |
3.49 |
3.49 |
0.00 |
19.08 |
0.81 |
3.38 |
1.77 |
29.27 |
1.08 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
300 |
Mean |
15.60 |
15.60 |
0.00 |
106.70 |
6.94 |
14.80 |
5.51 |
143.13 |
9.76 |
SD |
2.17 |
2.17 |
0.00 |
13.11 |
0.44 |
2.66 |
5.60 |
22.54 |
0.97 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
1000 |
Mean |
16.40 |
16.20 |
5.50 |
115.50 |
7.10 |
15.60 |
13.30 |
163.63 |
9.46 |
SD |
5.44 |
5.67 |
15.71 |
41.59 |
0.55 |
5.82 |
30.67 |
22.38 |
0.74 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
9 |
9 |
Table 4: Sex ratio of pups – Group mean data
Treatment (mg/kg/bw/d) |
|
At birth |
On day 4 post-partum |
||||||
Males |
Females |
Total |
% Males |
Males |
Females |
Total |
% Males |
||
0 |
Mean |
6.90 |
8.70 |
15.60 |
49.67 |
6.40 |
8.00 |
14.40 |
49.66 |
SD |
2.02 |
4.03 |
5.27 |
19.96 |
1.71 |
3.59 |
4.60 |
19.93 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
100 |
Mean |
6.90 |
7.30 |
14.20 |
50.50 |
6.80 |
7.30 |
14.10 |
50.14 |
SD |
1.79 |
2.95 |
3.49 |
15.38 |
1.81 |
2.95 |
3.38 |
15.72 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
300 |
Mean |
6.20 |
9.40 |
15.60 |
39.23 |
5.90 |
8.90 |
14.80 |
39.36 |
SD |
2.20 |
1.65 |
2.17 |
11.28 |
2.08 |
1.66 |
2.66 |
10.29 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
1000 |
Mean |
9.10 |
7.30 |
16.40 |
55.58 |
9.56* |
7.78 |
17.33 |
55.66 |
SD |
3.57 |
3.62 |
5.44 |
12.47 |
2.24 |
2.86 |
2.06 |
12.97 |
|
n |
10 |
10 |
10 |
10 |
9 |
9 |
9 |
9 |
*= mean value of group is significantly different from control
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 2 due to read-across) from a reference substance with similar structure and intrinsic properties. Read-across is justified based on common precursors and breakdown products of hydrolysis and consistent trends in environmental fate, ecotoxicological and toxicological profile (refer to the endpoint discussion for further details).
The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VIII - IX, 8.7, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
There are no data on the reproduction toxicity of 2-octyldodecyl myristate (CAS 22766-83-2). The assessment was therefore based on a study conducted with an analogue substance as part of a read-across approach, which is in accordance with Regulation (EC) No. 1907/2006, Annex XI, 1.5. For each specific endpoint the source substance(s) structurally closest to the target substance is/are chosen for read-across, with due regard to the requirements of adequacy and reliability of the available data. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the analogue read-across approach is provided in the technical dossier (see IUCLID Section 13) and within Chapter 5.1 of the CSR.
Toxicity to reproduction
CAS 22393-85-7
A combined repeated dose toxicity and reproduction/developmental toxicity screening study was performed according to OECD Guideline 422 under GLP conditions (Rossiello, 2014). 10 rats/sex/dose were administered 0, 100, 300 and 1000 mg/kg bw/day tetradecyl oleate (CAS 22393-85-7) once daily, via gavage. Males were exposed for 28-29 days, from two weeks before mating on test day one until after mating. Females were exposed for 54 days (during 2 weeks prior to mating, during mating, during post-coitum, and during 3 days of lactation).
No treatment-related parental effects were seen on viability, clinical signs, body weight (gain), food consumption, haematological parameters, clinical chemistry parameters, during observational and neurological screening, and during macroscopic and microscopic examinations. Therefore the NOAEL for parental systemic toxicity was ≥ 1000 mg/kg bw/day.
In parental animals, no effects on reproductive function (qualitative sperm staging, oestrus cycle) or performance (male and female mating and fertility indices, conception index, precoital interval, and number of corpora lutea and implantation sites, gestation length) were observed, compared with the control animals. The testis weight, epididymis weight, and histological examination of the testes in males as well as the weight and histological examination of the uterus and ovaries in females did not reveal any substance-related effects in the parental animals. All the pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two females in the control group had unilateral implantation, which is not considered to be treatment-related.
Therefore, a NOAEL for parental fertility of ≥ 1000 mg/kg bw/day was derived for male and female rats.
Overall conclusion for effects on fertility
There are no available studies on the toxicity to reproduction and fertility of 2-octyldodecyl myristate. Therefore analogue read-across from a source substance was applied. The potential for reproductive toxicity of the source substance (tetradecyl oleate, CAS 22393-85-7) was assessed in a reproductive/developmental screening study (OECD 422). The NOAEL value for fertility was at the currently applied limit dose value of 1000 mg/kg bw/day. Therefore, no hazard to reproduction was identified. Based on the available data and following the analogue approach, the target substance 2-octyldodecyl myristate is considered to not affect fertility.
Short description of key information:
Oral: OECD 422, rat, NOAEL fertility ≥ 1000 mg/kg bw/day
Oral: OECD 422, rat , NOAEL systemic ≥ 1000 mg/kg bw/day
Justification for selection of Effect on fertility via oral route:
Hazard assessment is conducted by means of read-across from a structural analogue. The selected study is the most adequate and reliable study based on the identified similarities in structure and intrinsic properties between source and target substance and overall assessment of quality, duration and dose descriptor level (refer to the endpoint discussion for further details).
Effects on developmental toxicity
Description of key information
Oral: OECD 422, rat, NOAEL development ≥ 1000 mg/kg bw/day
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 2 due to read-across) from a reference substance with similar structure and intrinsic properties. Read-across is justified based on common precursors and breakdown products of hydrolysis and consistent trends in environmental fate, ecotoxicological and toxicological profile (refer to the endpoint discussion for further details).
The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VIII, 8.7, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for read-across
There are no available data on the reproduction toxicity of 2-octyldodecyl myristate (CAS 22766-83-2). The assessment was therefore based on a study conducted with an analogue substance as part of a read-across approach, which is in accordance with Regulation (EC) No. 1907/2006, Annex XI, 1.5. For each specific endpoint the source substance(s) structurally closest to the target substance is/are chosen for read-across, with due regard to the requirements of adequacy and reliability of the available data. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the analogue read-across approach is provided in the technical dossier (see IUCLID Section 13) and within Chapter 5.1 of the CSR.
Developmental toxicity/teratogenicity
CAS 22393-85-7
A combined repeated dose toxicity and reproduction/developmental toxicity screening study was performed according to OECD Guideline 422 under GLP conditions (Rossiello, 2014). 10 rats/ sex/dose were administered 0, 100, 300 and 1000 mg/kg bw/day tetradecyl oleate (CAS 22393-85-7) once daily, via gavage. Males were exposed for 28-29 days, from two weeks before mating on test day one until after mating. Females were exposed for 54 days (during 2 weeks prior to mating, during mating, during post-coitum, and during 3 days of lactation).
The results of the offspring (viability) parameters pre-implantation loss, pre-birth loss, stillbirths, live births, cumulative pup loss on day 4 post-partum, litter size and pup weight were comparable between control and treatment group. Clinical signs of pups such as pallor, cold to touch, small and/or bruised muzzle, were observed in control and treatment groups and were therefore not considered to be of toxicological relevance. The number of male pups was significantly increased compared with the control group on Day 4 only. As the sex ratio (absolute percentage of males to females) was not significantly different from control , this is not considered to be a toxicologically relevant effect. The gross pathological examinations did not reveal any treatment-related effects. Based on the lack of effects, the NOAEL for developmental toxicity/teratogenicity is considered to be ≥ 1000 mg/kg bw/day.
Overall conclusion fordevelopmental toxicity/teratogenicity
There are no available studies on the developmental toxicity and teratogenicity of 2-octyldodecyl myristate. Therefore analogue read-across from a source substance was applied. The potential for developmental toxicity and teratogenicity of the source substance (tetradecyl oleate, CAS 22393-85-7) was assessed in areproductive/developmental screening study (OECD 422). NOAEL values for developmental toxicity/teratogenicity were all at the currently applied limit dose value of 1000 mg/kg bw/day. Therefore, no hazard to reproduction was identified. Based on the available data and following the analogue approach, the target substance 2-octyldodecyl myristate is considered to be not toxic to development.
Justification for selection of Effect on developmental toxicity: via oral route:
Hazard assessment is conducted by means of read-across from a structural analogue. The selected study (OECD 422) is the most adequate and reliable study based on the identified similarities in structure and intrinsic properties between source and target substance and overall assessment of quality, duration and dose descriptor level (refer to the endpoint discussion for further details).
Justification for classification or non-classification
According to Article 13 of Regulation (EC) No. 1907/2006 "General Requirements for Generation of Information on Intrinsic Properties of substances", information on intrinsic properties of substances may be generated by means other than tests e.g. from information from structurally related substances (grouping or read-across), provided that conditions set out in Annex XI are met. Annex XI, "General rules for adaptation of this standard testing regime set out in Annexes VII to X” states that “substances whose physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity may be considered as a group, or ‘category’ of substances. This avoids the need to test every substance for every endpoint". Since the analogue concept is applied to 2-octyldodecyl myristate (CAS 22766-83-2), data will be generated from data for reference source substance(s) to avoid unnecessary animal testing. Additionally, once the analogue read-across concept is applied, substances will be classified and labelled on this basis.
Based on the analogue read-across approach, the available data on toxicity to reproduction does not meet the classification criteria according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and is therefore conclusive but not sufficient for classification.
An OECD Guideline 422 study will not provide evidence for definite claims of no reproduction/ developmental effects. However, since no adverse effects on reproduction and development was noted up to and including the limit dose of 1000 mg/kg bw/day, the conclusion of no classification (conclusive but not sufficient for classification) is considered to be justified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.